ArticleTherapeutic advances in musculoskeletal disease2024

Switching from rituximab originator to GP2013 or CT-P10 biosimilars in autoimmune rheumatic diseases: drug retention rate and safety data from a multicentric retrospective cohort.

Stefano Gentileschi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.